Stay updated with breaking news from Primary Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In main results from the phase 3 trial, as well as those from an open-label extension, the investigational drug also proved its ability to positively influence several noninvasive efficacy outcomes.
The positive opinion is based on Phase 3 GLOW and Phase 2 CAPTIVATE study results, which investigated the efficacy and safety of ibrutinib plus venetoclax in patients with previously untreated CLL1
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical
/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 ...